| Trial ID # | NCT04152499 |
| Phase | I/II |
| Drug Class | Antibody Drug Conjugates: TROP2 |
| Drug Name | Sacituzumab tirumotecan |
| Alternate Drug Names | sac-TMT, MK-2870, SKB264 |
| Drugs in Trial | Sacituzumab tirumotecan |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 35, at least 2 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, evaluated per RECIST |
| Efficacy | ORR: 37.1% (13PR) |
| Clinically Significant Adverse Events | Serious AE: overall (37.5%) |
| Conclusion | Sacituzumab tirumotecan (Sac-TMT) monotherapy shows promising anti-tumor activity with a manageable safety profile in patients with platinum resistant or refractory ovarian cancer |
| Reference | Wang D et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. Ann Oncol (2024) 35 (2) abstract 715MO Wang D et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. Ann Oncol (2024) 35 (2) abstract 715MO |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.